Cetuximab

Cetuximab is another chimeric monoclonal antibody that has recently been approved to treat colorectal cancer. It is believed to exert its antineoplastic effect by targeting the epidermal growth factor receptor on the surface of cancer cells and interfering with their growth.It is used in combination with irinotecan and oxaliplatin for metastatic colon cancer and is used in combination with radiation for head and neck cancer. Like other antibodies, it is administered IV. Cetuximab has caused difficulty breathing and low blood pressure during the first treatment, and interstitial lung disease has been reported. Its primary toxicity is skin rash and a hypersensitivity infusion reaction.